摘要
目的：探讨肺癌组织中Ezrin与pAkt表达的临床病理学意义及二者相关关系。方法：采用免疫组化二步法检测75例肺癌及16例正常肺组织中Ezrin与pAkt的表达，并分析两种蛋白表达与临床病理特征的关系以及二者的相关性。结果：1）Ezrin蛋白在肺癌组织中阳性表达率（77.3％）低于正常肺组织（100％），二者比较差异具有统计学意义（χ^2=4．460，P=0．036）；Ezrin蛋白表达水平与肺癌患者年龄、性别、吸烟史、原发肿瘤大小，病理类型、分化程度等均无关，与有无区域淋巴结转移及远处转移有关。2）pAkt蛋白在正常肺组织中全部阴性表达，而在肺癌组织中阳性表达率为68．0％，二者比较差异具有统计学意义（χ^2=6．954，P=0．005）。pAkt蛋白表达水平与肺癌患者年龄、性别、吸烟史、原发肿瘤大小、病理类型、有无区域淋巴结转移及远处转移等无关，与分化程度及肺癌分期有关。3）使用Spearman相关分析显示Ezrin与pAkt的表达无显著相关（r=-0．137，P=0．236）。结论：Ezrin在肿瘤肺癌组织表达下调，在肺癌的侵袭转移过程中可能发挥重要作用，有可能成为肿瘤治疗的良好靶点。pAkt在肺癌组织表达上调，可能在肺癌晚期发挥更强的作用。Ezrin低表达的肿瘤，Ezrin可能通过pAkt以外路径参与肿瘤的进展，也可能在pAkt上游或间接通过pAkt路径发挥作用。
Purpose： To investigate the clinical significance of ezrin and pAkt expression in human lung carcinoma, and to study the correlation between them. Methods： Ezrin and pAkt expression was detected by two-step immunohistochemical staining using paraffin-embedded tumor tissues from 75 lung carcinoma cases and 16 normal lung cases with benign disease. Their correlation was analyzed. Results： The positive expression ratio of ezrin （77.3%） was significantly lower in lung carcinoma tissues than in normal tissues （100%） （P〈0.05）, and the downregulated expression of ezrin was significantly correlated with lymph node metastasis and distant tumor metastasis （P〈0.05）. The positive expression ratio of pAkt in lung carcinoma tissues （68.0%） was higher than in normal tissues （0） （P〈0.05）, and the upregulated expression of pAkt was significantly correlated with the differentiation of lung carcinoma and the clinical stages （P〈0.05）. There was no statistical correlation between the expression of ezrin and pAkt （r=-0.137,P=0.236）. Conclusion： Expression of ezrin is downregulated in lung carcinoma. Ezrin may perform a suppressive role in tumor progression and it may play important roles in the genesis and development of lung carcinoma.Protein of ezrin may be a good target for anti-metastasis therapy. Expression of pAkt is upregulated in lung carcinoma. Overexpression of pAkt may promote the progression of human lung carcinoma. Ezrin may be an upstream regulator of AKT or may be involved in tumor growth suppression through the way of AKT indirectly. Otherwise Ezrin may not act via the AKT pathway.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2010年第10期561-565,共5页
Chinese Journal of Clinical Oncology
基金
973国家重大科学研究计划基金(编号:2007CB914804)
天津市应用基础及前沿技术研究计划资助(编号:09JCYBJC10800)~~
